Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6

Lecia V. Sequist, MD
Published Online: Thursday, Oct 30, 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Over the past several years, 7 trials have examined erlotinib and gefitinib compared with chemotherapy for the treatment of lung cancer patients with EGFR mutations. These studies have all shown progression-free survival (PFS) and objective response benefit with the EGFR inhibitors.

Sequist says the PFS data from LUX-Lung 3 and LUX-Lung 6 led to the approval of afatinib in many countries. Identical results were seen between the two studies — there was no survival advantage between afatinib and chemotherapy, though patients with different EGFR mutations experienced varying degrees of benefit.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Over the past several years, 7 trials have examined erlotinib and gefitinib compared with chemotherapy for the treatment of lung cancer patients with EGFR mutations. These studies have all shown progression-free survival (PFS) and objective response benefit with the EGFR inhibitors.

Sequist says the PFS data from LUX-Lung 3 and LUX-Lung 6 led to the approval of afatinib in many countries. Identical results were seen between the two studies — there was no survival advantage between afatinib and chemotherapy, though patients with different EGFR mutations experienced varying degrees of benefit.

<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Informed Decision Making in Advanced NSCLC: Matching Treatment to PatientOct 25, 20171.0
Community Practice Connections™: 17th Annual International Lung Cancer Congress®Oct 31, 20171.5
Publication Bottom Border
Border Publication